VETERINARY TEAM REFERENCE

DEA & state schedules

Scheduling applies to the medication, not to the patient. This independent reference is not affiliated with the DEA.

Frunevetmab

FEDERAL STATUS

Not federally scheduled

The identified ingredients in this entry are not listed in the reviewed federal schedules. Prescription-only status, product restrictions and state law are separate questions.

Federal source ↗

State / prescribing or dispensing jurisdiction

STATE STATUS

Select a jurisdiction

Choose the state relevant to prescribing or dispensing. Patient residence alone may not determine every applicable rule.

What each federal schedule means

Highlighted rows match the verified federal or selected state schedule. The schedule describes legal control and abuse potential; it does not rank clinical usefulness or establish a dose.

Federal Schedules I–V: meaning and practice implications
Schedule	Meaning and practice
I	High abuse potential; no currently accepted medical use in U.S. treatment; lacks accepted safety under medical supervision. In practice: Not available for routine veterinary prescribing. Authorized research is a separate pathway.
II	High abuse potential; accepted medical use, sometimes with severe restrictions; abuse can cause severe dependence. In practice: No prescription refills under federal law. Strict prescribing, security and record requirements apply.
III	Less abuse potential than I or II; accepted medical use; abuse can cause moderate or low physical dependence or high psychological dependence. In practice: Federal prescriptions allow up to five authorized refills within six months. State rules may be stricter.
IV	Lower abuse potential than III; accepted medical use; limited dependence risk relative to III. In practice: The same federal five-refill / six-month prescription limit applies. Controlled-drug handling still applies.
V	Lower abuse potential than IV; accepted medical use; limited dependence risk relative to IV. In practice: Still controlled. Check authorized refills and state limits; do not automatically apply the III–IV refill rule.

What this means for the chart

For a controlled medication, confirm the prescriber’s authority for the applicable schedule, the exact formulation and quantity, authorized refills, secure handling, and required inventory / dispensing records. Check the state’s veterinary rules and any prescription monitoring program (PDMP) requirements or exemptions.

A PDMP reporting requirement does not by itself make a drug scheduled. “Not federally scheduled” does not mean over the counter, risk-free, or exempt from state law. States may use additional categories, such as Schedule VI, outside the federal I–V system.

← Medication & Supplement Reference

VETERINARY TEAM REFERENCE · MEDICATION

Frunevetmab

A feline monoclonal antibody targeting nerve growth factor. Solensia is labeled to control pain associated with osteoarthritis in cats.

Felinized anti-NGF monoclonal antibodyProduct-specific clinical reference

Updated October 16, 2026 · Sources and review status below

For veterinarians and veterinary staff. Product-label information is distinct from extra-label clinical practice. This is not a complete prescribing formulary or an automated interaction screen. Verify the current label, exact formulation, patient and species-specific clinical reference before use. Independent veterinary/pharmacy review remains pending.

Prescribing overview

Solensia controls feline osteoarthritis pain by targeting nerve growth factor. Review the updated October 2026 client information before every injection.

Key prescribing checks

Do not administer to cats with known hypersensitivity to frunevetmab.
The label excludes breeding cats and pregnant or lactating queens because of potential reproductive and offspring risks.
Review patient age, body weight and concurrent treatment against the complete label; a familiar osteoarthritis diagnosis does not settle every eligibility issue.
Review and provide the Client Information Sheet before each injection. The FDA’s October 5, 2026 labeling update adds post-approval reports including severe skin reactions, neurologic and urinary signs, and cases ending in death or euthanasia. Spontaneous reports do not establish frequency or causality; investigate new signs and reassess continued treatment.

Uses by species

Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.

Cats

FDA-approved Solensia indication

Osteoarthritis pain

Not for breeding, pregnant or lactating cats.

Use / indication source ↗

Pharmacology & pharmacokinetics

Mechanism and clinical role

Binds NGF and reduces signaling through TrkA/p75NTR involved in pain sensitization.

Absorption, distribution, metabolism and elimination

Osteoarthritic cats studied at 3 mg/kg subcutaneously: median peak 7 days, mean half-life 11 days.

SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC

Contraindications & cautions

Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.

Solensia

U.S. feline subcutaneous-injection label, updated October 2026.

Contraindications · when not to use

Known frunevetmab hypersensitivity; breeding, pregnant or lactating cats.

Precautions & monitoring

Younger/smaller cats and prolonged treatment have evaluation limits; review current client information before each injection.

Safety sources checked: October 16, 2026. Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.

Adverse effects

2026 postapproval reports include severe skin reactions, neurologic/urinary signs, anaphylaxis and death/euthanasia; reports cannot establish incidence or causation.

These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.

Dosing & administration

Verify the source before prescribing. The regimens below summarize selected veterinary product labels, not every accepted veterinary use. They are not automatic substitutions between brands or formulations. Renal/hepatic disease, concurrent therapy, age, indication and clinical response can require a different plan.

Selected product-label regimens — not a patient-specific prescription
Species & indication	Labeled regimen	Eligibility & source
Cats ≥7 months, 2.5–14 kgOsteoarthritis painSolensia 7 mg/mL injection	2.5–7 kg: 1 mL; 7.1–14 kg: 2 mL Subcutaneous · Once monthly Ongoing treatment requires reassessment	Minimum target 1 mg/kg; full contents of 1 or 2 single-use vials. Use immediately after withdrawal. Verify full dosing label ↗

Concurrent NSAID safety is unestablished.

Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗

Drug & supplement interactions

This is a selected interaction reference, not an automated or comprehensive combination checker. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.

Solensia

U.S. feline subcutaneous-injection label, updated October 2026.

Concurrent NSAID and other monoclonal-antibody safety is unestablished; vaccine interactions were not evaluated.

Interaction source ↗

Monitoring

Track mobility and new illness after injections.

Client counseling

Promptly report severe itching, weakness, imbalance, seizures or increased drinking/urination.

This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.

Storage & handling

Upright at 2–8°C, light-protected; never freeze; discard remainder.

Brands, formulations & ingredient identity

Active ingredients

Frunevetmab

Frunevetmab is a biological medication, not a supplement, NSAID or corticosteroid.

Solensia is species-specific. Canine bedinvetmab products are different antibodies and must not be treated as generic or brand synonyms.

Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.

Solensia

Formulation: Subcutaneous injection
Label / product scope: Cats

Feline anti-NGF monoclonal antibody for osteoarthritis pain.

Product label / source ↗

References & review status

Clinical reference updated October 16, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.

01DailyMed: Solensia, October 2026 label ↗02FDA: Solensia safety-label update, October 5, 2026 ↗

Search another medication or supplement →

Prescribing overview

Key prescribing checks

Uses by species

Cats

Pharmacology & pharmacokinetics

Mechanism and clinical role

Absorption, distribution, metabolism and elimination

Contraindications & cautions

Contraindications · when not to use

Precautions & monitoring

Adverse effects

Dosing & administration

Drug & supplement interactions

Solensia

Monitoring

Client counseling

Storage & handling

Brands, formulations & ingredient identity

Active ingredients

Solensia

References & review status

Related Resources